USP Posts Revised Heparin Monographs

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Pharmacopeia (USP) posted revised monographs for heparin sodium and heparin calcium on its website.

Rockville, MD (June 18)-The US Pharmacopeia (USP) posted revised monographs for heparin sodium and heparin calcium on its website. The US Food and Drug Administration asked USP to revise the heparin standards following recent reports of serious injuries and deaths associated with heparin containing adulterated active pharmaceutical ingredients from China.

The new monographs are Stage 1 revisions. On its website, USP says the revisions are intended to rapidly address the public-health crisis and ensure an unadulterated heparin supply. The organization improved the resolution of FDA’s capillary electrophoresis (CE) method by changing the concentration of heparin to 2 mg/mL and the injection time to 30 s.

USP is at work on Stage 2 revisions of the monographs, which will consider new methodologies for identification, introduce a new potency assay, and describe tests for impurities. Changes to USP’s heparin-product monographs and low-molecular-weight heparins also will be considered in the Stage 2 revisions.

The organization states that CE and nuclear magnetic resonance methods are needed to quickly allow for a qualified supply of heparin and to address the current adulteration of the heparin supply. These methods will be a provisional solution until Stage 2 revisions are complete. USP releases methods that have been validated with specific parameters and recommends that manufacturers validate the methods before using them.

In addition to the revised monographs, USP posted two new and two existing reference standards on its website. The new reference standards are “USP Heparin Sodium Identification RS” and “USP Heparin System Suitability RS.” The old reference standards are “USP Endotoxin RS” and “USP Heparin Sodium RS.” The current “USP Heparin Sodium, Lot L” reference standard is not affected by the revision and is not for use in the new identity tests. USP’s sodium heparin reference standard is still for use in the sheep-plasma clotting assay.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes